以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 国际医学(000516.SZ)发布异动公告，当前公司基本面未发生重大变化，公司以大健康医疗服务和现代 医学技术转化应用为主业，下属医疗机构主要为患者提供高水平的综合性医疗服务。公司目前不涉及脑 机接口产品的研发、生产及销售，脑机接口在医疗领域的相关应用目前正处于从实验室走向临床应用的 关键过渡阶段，公司旗下医疗机构应用的与脑机接口相关的康复训练系统及手术带来的收入占公司营业 收入比重极小，对公司业绩基本没有影响。 ...

国际医学发布异动公告称，当前公司基本面未发生重大变化，公司以大健康医疗服务和现代医学技术转 化应用为主业，下属医疗机构主要为患者提供高水平的综合性医疗服务。公司目前不涉及脑机接口产品 的研发、生产及销售，脑机接口在医疗领域的相关应用目前正处于从实验室走向临床应用的关键过渡阶 段，公司旗下医疗机构应用的与脑机接口相关的康复训练系统及手术带来的收入占公司营业收入比重极 小，对公司业绩基本没有影响。敬请广大投资者注意二级市场公司股票交易风险，理性决策，审慎投 资。 ...

【2连板国际医学：目前不涉及脑机接口产品的研发、生产及销售 旗下医疗机构应用的与脑机接口相关 的业务收入占营业收入比重极小】智通财经1月14日电，国际医学(000516.SZ)发布异动公告，当前公司 基本面未发生重大变化，公司以大健康医疗服务和现代医学技术转化应用为主业，下属医疗机构主要为 患者提供高水平的综合性医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，脑机接口在医 疗领域的相关应用目前正处于从实验室走向临床应用的关键过渡阶段，公司旗下医疗机构应用的与脑机 接口相关的康复训练系统及手术带来的收入占公司营业收入比重极小，对公司业绩基本没有影响。 转自：智通财经 ...

国际医学1月14日公告，公司股票连续三个交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异 常波动。当前公司基本面未发生重大变化，公司以大健康医疗服务和现代医学技术转化应用为主业，下 属医疗机构主要为患者提供高水平的综合性医疗服务。公司目前不涉及脑机接口产品的研发、生产及销 售，脑机接口在医疗领域的相关应用目前正处于从实验室走向临床应用的关键过渡阶段，公司旗下医疗 机构应用的与脑机接口相关的康复训练系统及手术带来的收入占公司营业收入比重极小，对公司业绩基 本没有影响。敬请广大投资者注意二级市场公司股票交易风险，理性决策，审慎投资。 ...

Core Insights - Shanghai Ruici Medical Investment Group and Shanghai Institute of Major Infectious Diseases and Biosecurity signed a strategic cooperation agreement to advance chronic disease health examination standards and collaborate in preventive medicine [1] Group 1: Strategic Cooperation - The agreement aims to establish scientific health examination standards and address potential health management needs [1] - Both parties will leverage their strengths in medical services and technological innovation to enhance public health services and cultivate medical research talent [1] Group 2: Organizational Background - The Shanghai Institute of Major Infectious Diseases and Biosecurity was approved by the Shanghai Municipal Government in July 2020 and officially established in November 2020 [2] - It operates as a public welfare research institution jointly built by the Shanghai Municipal Government and Fudan University, managed under a council-led system [2]

Group 1 - The core point of the news is that International Medicine (000516) has seen significant share pledges from its major shareholders, indicating potential liquidity issues [1] - Shareholder Shaanxi Century Xinyuan Commercial Management Co., Ltd. has pledged a total of 75 million shares, accounting for 3.35% of the total share capital [1] - As of the announcement date, Shaanxi Century Xinyuan has pledged a total of 506 million shares, which is 82.07% of its total holdings, while shareholder Shenhua Holdings Group Co., Ltd. has pledged 45.31 million shares, representing 74.91% of its holdings [1] Group 2 - International Medicine reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94% [1] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year, and the net profit after deducting non-recurring gains and losses was -312 million yuan, a decline of 41.94% [1] - In Q3 2025, the company recorded a single-quarter revenue of 961 million yuan, a decrease of 18.95% year-on-year, with a net profit of -129 million yuan, reflecting a significant drop of 234.24% [1] - The company's debt ratio stands at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [1] Group 3 - The main business of International Medicine includes health care services and the application of modern medical technology [2]

新京报讯（记者陈琳）北京市东城区第十七届人民代表大会第六次会议正在举行。1月14日，东城区卫 生健康委主任曾文军介绍，2025年东城区人均预期寿命达84.59岁，位居全国前列。 强化基层服务能力，开展家庭病床服务试点，开展居家医养联合体试点建设，推动社区卫生与养老服务 资源整合衔接。深化疾控体系改革，推进智慧疾控建设，完善智能监测预警体系，建设区级慢病防治管 理中心。 2025年，东城区医疗资源布局持续优化，医联体建设取得新突破，区第一人民医院新址开诊后门急诊人 次同比增长7%，9家区级医院实现检查检验结果线上共享互认。 基层医疗服务网络进一步夯实，社区医疗机构上转和接收下转人次数同比增长超20%。推动第六医院医 疗集团、和平里医院医疗集团建设，构建网格化医疗服务新格局。在中医药发展方面，东城区获评国家 中医药传承创新发展示范项目试点，打造前门广誉远（600771）"博物馆+国药堂+国医馆"一体化发展 模式，推动"中医药+"融合发展。 在重点人群健康服务上，家庭医生签约服务与居家养老实现深度融合，连续9年获全市基层卫生绩效考 核优秀。针对老年人群，搭建区级老年痴呆全病程服务协作网；保障母婴健康，辖区早孕门诊建 ...

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical and biotechnology sector, indicating a positive outlook for investment opportunities [3]. Core Insights - The pharmaceutical sector has shown a strong performance with a 7.81% increase in the index, outperforming the CSI 300 index by 5.03 percentage points, ranking 6th in industry performance [9][14]. - The report highlights significant growth in sub-sectors such as medical services and medical devices, with increases of 12.34% and 9.42% respectively [17][22]. - The report emphasizes the potential of small nucleic acid drugs, predicting a market valuation of $18.6 billion by 2029, with a CAGR of 29.5% from 2024 to 2029 [38]. - The upcoming JPMorgan Healthcare Conference is expected to showcase over 20 Chinese companies, with a focus on significant R&D advancements [39]. Summary by Sections Market Review - The pharmaceutical index increased by 7.81% this week, outperforming the CSI 300 index by 5.03 percentage points, ranking 6th in industry performance [14]. - The best-performing sub-sector this week was medical services, which rose by 12.34%, while traditional Chinese medicine had the smallest increase at 2.89% [17][22]. Individual Stock Performance - In the A-share market, 453 out of 478 pharmaceutical stocks rose, with the top five performers being Bibet (+68.89%), Innovation Medical (+61.04%), and Sanbo Brain Science (+56.15%) [25]. - In the Hong Kong market, 104 out of 116 pharmaceutical stocks increased, with the top performers including Zhaoyan New Drug (+30.76%) and Rongchang Bio (+28.51%) [29]. Industry News and Policies - The National Health Commission has outlined ten key initiatives for 2026, focusing on enhancing pediatric services and mental health care [32]. - The National Medical Products Administration has announced the establishment of two industry standards for brain-computer interface medical devices, indicating a regulatory push for this technology [32]. Weekly Insights - The report notes that the pharmaceutical sector is experiencing a "New Year Rally" driven by favorable policies for brain-computer interfaces and the launch of small nucleic acid innovative drugs [36]. - The report suggests monitoring companies involved in brain-computer interfaces, such as Chengyitong and Weisi Medical, as they are in the R&D phase [37].

新里程公告称，公司股票交易价格连续2个交易日（2026年1月13日和14日）收盘价格涨幅偏离值累计超 20%，属异常波动。经核查，公司前期披露信息无需更正、补充，经营环境未变，生产正常，公司及控 股股东无应披露未披露重大信息，控股股东在波动期间无买卖公司股票情形。公司预计4月3日披露2025 年年报，提醒投资者关注指定媒体信息，注意风险。 ...

证券之星消息，1月14日医疗服务板块较上一交易日上涨0.8%，诺思格领涨。当日上证指数报收于 4126.09，下跌0.31%。深证成指报收于14248.6，上涨0.56%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出24.65亿元，游资资金净流入4.18亿元，散户资金 净流入20.48亿元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...